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Introduction
Small interfering RNAs (siRNAs) have emerged as molecules 
with high potential to silence critical molecular pathways 
involved in tumor progression. However, to harness the full 
potential of this treatment modality in the clinical arena, intel-
ligent nanoparticle delivery systems need to be developed 
in tandem. This is crucial since siRNAs have been shown to 
lack the capacity to be transfected into cells on their own due 
to their relatively high polarity and molecular size.1 To deliver 
siRNA to an intracellular target, a nanoparticle delivery sys-
tem is often used to “mask” the negative charges on these 
molecules. The small size of these nanoparticles facilitates 
endocytosis, enabling the internalization of siRNAs while pre-
venting degradation within the lysosomes.2 Naked (unencap-
sulated) siRNA are also degraded by serum endonucleases 
and efficiently cleared from systemic circulation by glomeru-
lar filtration, resulting in a very short plasma half-life.3,4 Vari-
ous carriers have been studied as potential delivery vehicles 
for siRNA therapeutic. Such carriers include cell-penetrating 
peptides, lipid-based carriers, and polymeric and dendrimeric 
carriers.1,5,6 However, these delivery systems are still limited 
by major challenges.4 Therefore, there is an unmet need for 
a smart nanoparticle delivery system for efficient and stable 
siRNA transfection.
Recently, our group reported on a novel hybrid nanopar-
ticle delivery system for siRNA delivery. These nanoparticles, 
composed of human IgG and poloxamer-188, are designed 
to prevent immunogenic/inflammatory response in vivo and 
to reduce clearance by macrophages. These nanoparticles 
were able to successfully deliver siRNA to the cytosol of A549 
lung cancer cell lines without eliciting immunogenic/inflam-
matory response in murine macrophages, RAW 264.7.4,7 
Using these nanoparticles to deliver siRNA against mutant 
K-ras, a significant downregulation of both protein and mRNA 
of K-ras was achieved.4 Further, the enclosed siRNA was 
protected from nuclease in 50% serum for up to 48 hours.
The objective of the current study is to investigate the 
potential of these nanoparticles to selectively deliver the 
encapsulated siRNA to lung tumor in metastatic orthotopic 
murine models of non-small-cell lung cancer (NSCLC), fol-
lowing the functionalization of the nanoparticles with antineu-
rotensin receptor 1 monoclonal antibody (anti-NTSR1-mAb). 
We also aim to determine the pharmacokinetic parameters 
of the encapsulated siRNA (antimutant K-ras siRNA) in 
comparison to the naked siRNA. NTSR1 is being used as 
a target for delivery of these nanoparticles to lung tumor 
because NTSR1 has been shown by immunohistochemistry 
to be overexpressed in ~60% of lung adenocarcinoma.8 In 
early stages of NSCLC, NTSR1 was one of the first 50 genes 
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Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The use of this tool as a treatment 
modality is limited by lack of an intelligent carrier system to enhance the preferential delivery of this molecule to specific targets 
in vivo. In the present study, the in vivo behavior of novel anti-NTSR1-mAb-functionalized antimutant K-ras siRNA-loaded 
hybrid nanoparticles, delivered by i.p. injection to non-small-cell lung cancer in mice models, was investigated and compared 
to that of a naked siRNA formulation. The siRNA in anti-NTSR1-mAb-functionalized hybrid nanoparticles was preferentially 
accumulated in tumor-bearing lungs and metastasized tumor for at least 48 hours while the naked siRNA formulation showed 
lack of preferential accumulation in all of the organs monitored. The plasma terminal half-life of nanoparticle-delivered siRNA 
was 11 times higher (17–1.5 hours) than that of the naked siRNA formulation. The mean residence time and AUClast were 3.4 
and 33 times higher than the corresponding naked siRNA formulation, respectively. High-performance liquid chromatography 
analysis showed that the hybrid nanoparticle carrier system protected the encapsulated siRNA against degradation in vivo. 
Our novel anti-NTSR1-mAb-functionalized hybrid nanoparticles provide a useful platform for in vivo targeting of siRNA for both 
experimental and clinical purposes.
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upregulated and associated with disease-free survival.8 We 
hypothesize that this overexpression in NSCLC can be used 
to achieve an optimized targeting of siRNA to NSCLC by 
conjugating anti-NTSR1-mAb to the surface of our hybrid 
nanoparticles.
Results
Nanoparticle preparation, characterization, and in vitro 
assessment
Table 1 shows that the nanoparticles were ~135 nm in diam-
eter and the functionalization of these nanoparticles with anti-
NTSR1-mAb slightly increased the size of the nanoparticles 
to 140 nm. Prior to the functionalization of the nanoparticles, 
a zeta potential of +16.7 mV was recorded. However, the 
nanoparticles showed no charges following the functionaliza-
tion step. The encapsulation efficiency and loading capacity 
of antimutant K-ras siRNA in these nanoparticles were 60 
and 2%, respectively.
Scanning electron micrograph of the nanoparticles in 
Figure 1a confirms that the nanoparticles were mostly 
spherical in shape. The particles were fairly homogenous in 
morphology.
Figure 1b demonstrates the knockdown efficiency of these 
antimutant K-ras siRNA-loaded hybrid nanoparticles against 
G12S mutant K-ras normally expressed in A549 cells. These 
nanoparticles produced superior downregulation of G12S 
mutant K-ras when compared to lipofectamine 2000 as a 
transfection reagent.
Antiproliferative effect of these antimutant K-ras siRNA-
loaded nanoparticles in A549 cells is further demonstrated 
in Figure 1c. In contrast, scramble siRNA-loaded hybrid 
nanoparticles did not demonstrate any antiproliferative effect 
in A549 cells (Figure 1c).
Metastatic orthotopic murine model of NSCLC
Mouse models used for these were developed over a 3-week 
period. Following the injection of A549-luciferase cells into 
the tail vein of the mice, tumor burden was monitored using 
Xenogen IVIS bioluminescence imaging system. Tumor was 
initially established in the colorectal region after the first 
week. This tumor quickly metastasizes to the two lungs of the 
mice after 3 weeks of injection as seen in Figure 2.
Plasma pharmacokinetics
Antimutant K-ras siRNA was isolated from mice plasma using 
the analytical procedure described in Figure 6. Ion-pair high-
performance liquid chromatography (HPLC) analysis showed 
a linear standard curve ranging from 50 to 50,000 ng/ml 
(r = 0.9998). The lowest detection limit was 50 ng/ml. siRNA 
recovery from plasma following isolation with Clarity OTX 
isolation and ion-pair HPLC analysis was consistently above 
90%.
Figure 3 demonstrates the plasma concentration versus 
time curves when equivalent of 0.9 mg/kg of siRNA either 
naked or loaded into anti-NTSR1-mAb-functionalized hybrid 
nanoparticles. The maximum concentration (C
max
) of siRNA 
delivered by anti-NTSR1-mAb-functionalized hybrid nanopar-
ticles was 17289.5 ng/ml compared to 7504.9 ng/ml observed 
for the naked siRNA formulation. These maximum concentra-
tions were observed at 30 and 60 minutes (T
max
) for naked 
siRNA and siRNA in anti-NTSR1-mAb-functionalized hybrid 
nanoparticles, respectively. Figure 4 demonstrates the supe-
riority of using novel anti-NTSR1-mAb-functionalized hybrid 
Table 1 Particle size, PDI, and zeta potential analysis of nanoparticles measured by photon correlation spectroscopy
Nanoparticle batch
Particle 
size (nm) PDI
Zeta  
potential (mV)
Encapsulation  
efficiency (%)
Loading  
capacity (%)
Nanoparticles 135.4 ± 5.4 0.07 ± 0.03 +16.7 ± 0.2 60 ± 0.4 2.04 ± 0.06
Nanoparticles-anti-NTSR1-mAb 140.2 ± 2.4 0.2 ± 0.04 0.0 ± 0.3 N/A N/A
N/A, not applicable; PDI, polydispersity index.
Figure 1 Nanoparticle characterization and knockdown efficiency. (a) Scanning electron micrograph shows the spherical morphology 
of the nanoparticles. (b) Western blot analysis showing in vitro knockdown efficiency of siRNA nanoparticles against mutant G12S K-ras in 
A549 cells. Nano K-ras represents antimutant K-ras siRNA-loaded hybrid nanoparticles, naked K-ras represents unencapsulated antimutant 
K-ras siRNA, Nano Scr represents scramble siRNA-loaded hybrid nanoparticles, and lipo K-ras represents antimutant K-ras siRNA transfected 
using lipofectamine 2000. (c) MTT assay showing in vitro antiproliferative activity of antimutant K-ras siRNA nanoparticles in A549 cells, n = 5, 
***P ≤ 0.001.
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nanoparticles for siRNA delivery in murine models of lung 
cancer in comparison to the naked siRNA formulation.
Key pharmacokinetic parameters presented in Table 2 fur-
ther demonstrate the superiority of using these novel anti-
NTSR1-mAb-functionalized hybrid nanoparticles for siRNA 
delivery in murine models of lung cancer in comparison to 
the naked siRNA formulation.
Tissue distribution of siRNA in NSCLC murine models
Figure 4 demonstrates the discriminatory delivery of siRNA 
to tumor-bearing lungs by anti-NTSR1-mAb-functionalized 
hybrid nanoparticles over a 3-day period. In contrast, naked 
siRNA was not discriminatory in tissue delivery. After 5 hours, 
a significant accumulation of siRNA delivered by anti-NTSR1-
mAb-functionalized hybrid nanoparticles was observed in 
tumor-bearing lungs in comparison to the liver (P ≤ 0.05). On 
the second day after siRNA administration, an even more sig-
nificant accumulation in the lung tumor was observed when 
compared to the kidneys (P ≤ 0.01). On the third day after 
siRNA administration, total clearance was observed in the 
liver, heart, and kidney, leaving the lung tissue as the only 
tissue with siRNA accumulation.
In vivo stability of siRNA
In vivo stability of siRNA delivered by anti-NTSR1-mAb-
functionalized hybrid nanoparticles was compared to that of 
the naked siRNA using ion-pair HPLC-UV following siRNA 
isolation using Clarity OTX, an oligonucleotide extraction car-
tridge (Phenomenex, Torrance, CA). Blood samples collected 
by orbital puncture at 0-, 30-, and 90-minute and 24-, 25-, 
26-, and 48-hour time points were analyzed for signs of deg-
radation. The presence of single-stranded oligonucleotides in 
the naked siRNA samples was observed immediately after 
30 minutes of administration. However, degradation products 
were not observed in the corresponding sample for hybrid 
nanoparticle-delivered siRNA. Figure 5a demonstrates the 
presence of single-stranded oligonucleotides as well as the 
presence of higher molecular weight degradation products 
in the naked siRNA samples, 25 hours after administration. 
However, such degradation/metabolic products were not 
observed in the corresponding hybrid nanoparticle-delivered 
siRNA samples. The first sign of degradation in the hybrid 
nanoparticle-delivered siRNA samples was not observed 
until 48 hours postadministration. This confirms the ability of 
the hybrid nanoparticles to protect the encapsulated siRNA 
in vivo similar to what was observed in vitro.4
Discussion
This study presents the biodistribution and pharmacokinetics 
properties of siRNA encapsulated in an anti-NTSR1-mAb-
functionalized hybrid nanoparticles in comparison to naked 
siRNA. These hybrid nanoparticles combine the benefits 
derived from human immunoglobulin G (human IgG) and 
poloxamer-188 (polyoxyethylenepolyoxypropylene block 
copolymer), for stable and efficient siRNA delivery. Human 
IgG is the main antibody isotype found in blood, it is the main 
immunoglobulin that protects the body against infection. Since 
human IgG is part of the body’s natural defends mechanism, 
we hypothesized that a nanoparticle composing IgG would 
reduce the well-documented immunogenic reaction experi-
enced with most nanoparticle formulations. This hypothesis 
has been tested and proved to be correct.4 Poloxamer-188, 
a nonionic triblock copolymer, has been previously used as 
a stealth polymer to prevent macrophage uptake of nanopar-
ticles hence circumventing the reticuloendothelial system 
during systemic circulation. It was proposed that it reduces 
opsonization by serum proteins hence reducing macropha-
geal uptake.9,10 The combination of these two components in 
a single nanoparticle delivery system makes these nanopar-
ticles quite unique. In this study, hybrid nanoparticles were 
functionalized with anti-NTSR1-mAb to convert them into an 
actively targeted nanoparticle delivery system for delivering 
siRNAs to NSCLC cells using NTSR1 as a delivery target. 
NTSR1 has been shown by immunohistochemistry to be 
overexpressed in ~60% of lung adenocarcinoma.7 In early 
stages of NSCLC, NTSR1 was one of the first 50 genes 
upregulated and associated with disease-free survival.8 We 
aimed to take advantage of this overexpression in NSCLC to 
achieve an optimized targeting of siRNA to NSCLC by conju-
gating anti-NTSR1-mAb to the surface of our hybrid nanopar-
ticles. Anti-NTSR1-mAb was attached to the nanoparticles to 
Figure 2 SCID beige mice showing tumor burden in the lungs 
and colorectal region over a 3-week period.
Week 1 Week 3Week 2
Figure 3 siRNA plasma concentration over time. Tumor-bearing 
mice were given a single dose of 0.9 mg/kg of antimutant K-ras 
siRNA either in anti-NTSR1-mAb-functionalized nanoparticles or as 
naked siRNA. n = 3.
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the preformed nanoparticles by thiolating anti-NTSR1-mAb 
using 2-iminothiolane (Traut’s reagent) as reported previ-
ously.11,12 N-[p-maleimidophenyl] isocyanate was used as 
a heterobifunctional, sulfhydryl and hydroxyl-reactive linker 
and was conjugated to the hydroxyl groups present in polox-
amer-188 on the surface of the hybrid nanoparticles.13 The 
isocyanate end of N-[p-maleimidophenyl] isocyanate reacted 
with the hydroxyl group on the nanoparticles to form carba-
mate linkage while the maleimide end reacted with the sulf-
hydryl groups in the thiolated anti-NTSR1.14 The particle size 
of anti-NTSR1-mAb-functionalized nanoparticles was slightly 
higher than the corresponding nonfunctionalized nanoparti-
cles as shown in Table 1. Particle size, zeta potential, loading 
efficiency, and encapsulation efficiency of hybrid nanopar-
ticles presented in Table 1 have been previously reported by 
our group.7 The increase in size may be attributed to the con-
jugation of mAb to the surface of the nanoparticles. Further, 
the fact that several centrifugation steps and lyophilization 
were involved in the conjugation process may also contribute 
to the increase in particle size.12,13
Metastatic model of lung cancer developed in Figure 2 
shows that tumor was initially implanted in the colorectal 
region of the mice before finally metastasizing to the lung 
rather than the commonly observed trend of initial implanta-
tion in the lungs before metastasis to other areas of the body. 
This is because of the relatively lesser number (5 × 105) of 
A549-luciferase cells injected into the tail vain of the mice. 
Observations in our laboratory showed that when higher 
number of cells such as 5 × 106 was injected into the tail vain, 
initial implantation of tumor in the lung was observed.
One of the main limitations to the application of siRNA in 
translational medicine is the fact that they are very vulnerable 
to endonuclease enzymes found in body fluids.4 The rapid 
clearance of naked siRNA from the blood of the mice could 
be attributed to degradation by endonucleases in the blood. 
However, the hybrid nanoparticle delivery system offered 
protective armor to the siRNA when delivered using the anti-
NTSR1-mAb-functionalized hybrid nanoparticles, hence the 
lower clearance rate. The protection of the siRNA by the 
nanoparticle delivery system could also be responsible for 
the longer plasma terminal half-life and the higher mean resi-
dence time in comparison to the naked siRNA formulation.
Figure 4 demonstrates that siRNA delivered using anti-
NTSR1-mAb-functionalized hybrid nanoparticles were 
mostly accumulated in the lung after 5 hours. However, the 
liver and the kidney also had substantial amount of siRNA 
delivered at this time. The liver among other organs such as 
spleen belong to the reticuloendothelial system organs.15 
Liver is also a highly perfused organ; hence, nanoparticle 
carriers are rapidly distributed to this organ.15,16 Further, the 
microvessels of liver have relatively large fenestrations which 
allow entry of particles as high as ~200 nm.17 In view of this, 
systemically delivered nanoparticles usually accumulate in 
the liver and spleen.17 The kidney also demonstrated a high 
amount of siRNA probably because it is highly perfused and 
it is the main organ for elimination. However, after 24 hours, 
a more discriminatory delivery of siRNA to tumor-bearing 
lungs began to manifest due to the effect of the presence 
of anti-NTSR1-mAb on the hybrid nanoparticles coupled 
with the fact that tumors are naturally more permeable to 
the penetration of particles between 100 and 800 nm due 
to enhanced permeation and retention effect.1,15 After 48 
hours, siRNA from anti-NTSR1-mAb-functionalized hybrid 
nanoparticles could only be seen in the tumor-bearing lung 
and was completely cleared from other organs probably due 
to the interaction between anti-NTSR1-mAb on the surface 
of the nanoparticles and the NTSR1 receptors present in the 
tumor-bearing lungs. Out of curiosity, we wanted to know if 
Figure 4 In vivo biodistribution studies. Biodistribution of antimutant K-ras siRNA following i.p. injection of siRNA in (a) functionalized 
hybrid nanoparticles and (b) naked siRNA. Lung data statistically compared to the next highest accumulation in tissues of the same time point. 
*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. n = 3.
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Table 2 Key pharmacokinetic parameters of naked siRNA and  
siRNA-loaded anti-NTSR1-mAb-functionalized hybrid nanoparticles in 
SCID models of metastatic orthotopic non-small-cell lung cancer
Parameters Naked siRNA siRNA nanoparticles
C
max
 (ng/ml) 7504.9 17289.5
T
max
 (hour) 0.5 1
AUClast (hour.ng/ml) 13393.88 454089.63
CL/F (ml/minute/kg) 1.1 × 10−6 2.9 × 10−8
λ
z
 (1/hour) 0.4490 0.0408
T1/2 (hour) 1.5 17.0
MRT (hour) 6.6 22.6
VZ/F (l/kg) 1.5 × 10−4 4.23 × 10−5
AUClast, area under the plasma concentration–time curve from time zero to 
time of last measurable concentration; CL/F, apparent clearance; C
max
, peak 
plasma concentration; MRT, mean residence time; T1/2, plasma terminal 
half-life; T
max
, time to peak plasma concentration; VZ/F, apparent volume of 
distribution; λ
z
, elimination rate constant.
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anti-NTSR1-mAb-functionalized nanoparticles were able to 
deliver siRNA to metastasized tumor in the colorectal region. 
Tumor in this area was harvested in some mice and analyzed 
for siRNA delivery. A significant accumulation of siRNA was 
detected in these metastasized tumors. In contrast, naked 
siRNA formulation showed a conspicuous lack of selectivity 
in the delivery of siRNA to tumor-bearing lungs and other 
organs after 24 hours. Further, naked siRNA was also signifi-
cantly cleared from the tumor-bearing lungs after 48 hours.
In conclusion, Anti-NTSR1-mAb-functionalized hybrid 
nanoparticles were able to drive the pharmacokinetics and 
biodistribution of siRNA in tumor-bearing mice. These nano-
carriers were able to significantly reduce the clearance and 
increase the circulation time of siRNA in plasma when com-
pared to that of naked siRNA formulation. siRNA delivered 
to anti-NTSR1-mAb-functionalized hybrid nanoparticles were 
selectively delivered in tumor-bearing lungs over a period of 
48 hours. Hybrid nanoparticles also protected encapsulated 
siRNA from degradation in systemic circulation. Thus, these 
novel hybrid nanoparticles can serve as an effective nonviral 
vector for siRNA delivery.
Materials and methods
Chemicals and reagents. Human IgG was purchased from 
Equitech Bio (TX). Poloxamer-188, RNase-free water, and 
fetal bovine serum were obtained from Fisher Scientific. 
siRNA against mutated K-ras G12S was designed and 
purchased from Thermo Scientific (Rockford, IL; formerly 
Dharmacon). siG12S sense and antisense sequences 
are GUUGGAGCUAGUGGCGUAGdTdT and CUACGC-
CACUAGCUCCAACdTdT, respectively. Clarity OTX solid-
phase extraction was obtained from Phenomenex. Erlotinib 
hydrochloride and HPLC grade solvents were purchased 
Figure 5 In vivo stability studies. High-performance liquid chromatogram of (a) naked siRNA and (b) hybrid nanoparticle-delivered siRNA 
25 hours after i.p. administration to tumor-bearing mice. DS siRNA, double-stranded siRNA.
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from Fisher Scientific (Pittsburgh, PA). XenoLight RediJect 
D-Luciferin Bioluminescent Substrate was obtained from 
Perkin Elmer (Waltham, MA). Mouse antineurotensin recep-
tor 1 monoclonal antibody was purchased from Santa Cruz 
Biotechnology (Dallas, TX). Monoclonal antibodies specific 
for mutant G12S K-ras proteins was obtained from NewEast 
Biosciences, King of Prussia, PA. 
Cell culture. Human adenocarcinoma cell line A549-lucif-
erase, expressing K-ras mutation at G12S, was obtained 
from Perkin Elmer. They were maintained in F12K medium 
supplemented with 10% fetal bovine serum and 1% antibiot-
ics. They were kept in a humidified air atmosphere with 5% 
carbon dioxide.
Western blot analysis. Cells were washed twice with ice-
cold phosphate-buffered saline. Cell lysates were prepared 
in Pierce RIPA buffer (Thermo Scientific) with addition of 
Pierce Protease Inhibitor Mini Tablets (Thermo Scientific). 
The protein concentration was determined with the Coo-
massie Plus (Bradford) Assay Kit (Thermo Scientific). About 
80 µg of total proteins was separated on NuPAGE 4–12% 
Bis-Tris gels (Life Technologies, Carlsbad, CA) with NuPAGE 
MES SDS running buffer (Life Technologies) and subse-
quently transferred onto nitrocellulose membrane of 0.45 µm 
pore size (Life Technologies). The membrane with proteins 
was blocked according to manufacturer’s instructions (Invi-
trogen, Carlsbad, CA) for 1 hour at room temperature and 
probed with primary antibodies—K-ras G12S monoclonal 
antibody (1:500; New East Biosciences, Malvern, PA) and 
β-actin (1:5,000; Sigma-Aldrich, St. Louis, MO) overnight at 
4 °C. The membranes were washed three times for 5 min-
utes in wash buffer according to manufacturer’s instructions 
(Invitrogen) and incubated with secondary goat anti-mouse 
secondary antibodies, conjugated with horseradish peroxi-
dase (Molecular Probes, Eugene, OR) at a dilution 1:1,000. 
Immune complexes were detected with chemiluminescent 
substrate, Pierce ECL Western Blotting Substrate (Thermo 
Scientific) in a dark room on tabletop processor SRX-101A 
(Konica Minolta, Japan). Images were quantified in the 
ImageJ software.
Cytotoxicity assay. MTT assay was used to determine the 
effect of siG12S-loaded nanoparticles on the proliferation of 
A549 cells. Cells (1 × 104)/well were seeded in 96-well plates 
and incubated at 37 °C in a humidified atmosphere with 5% 
carbon dioxide for 24 hours. The cells were then treated with 
different concentrations of siG12S-loaded hybrid nanoparti-
cles and scramble-siRNA-loaded hybrid nanoparticles. Cells 
were incubated for 72 hours. About 10 µl of 12 mmol/l MTT 
reagent was then added to each well. This was then incu-
bated at 37 °C for 4 hours. The medium was aspirated and 
50 µl of sterile dimethyl sulfoxide was added to each well and 
mixed thoroughly with pipet. The cells were then incubated at 
37 °C for 10 minutes. The plate was read at 540 and 650 nm.
Animals. Female severe combined immunodeficient (SCID) 
beige mice, 7–8 weeks old and weighing ~25 g were sup-
plied by Taconic and maintained in the American Asso-
ciation for the Accreditation of Laboratory Animal Care 
(AAALAC)-accredited facility at Thomas Jefferson University. 
All animal studies were approved by the Institutional Animal 
Care and Use Committee of Thomas Jefferson University.
Preparation of siRNA-loaded hybrid nanoparticles. Hybrid 
nanoparticles were prepared based on our previously 
reported protocol.4 About 50 mg of excipient-free human 
IgG was dissolved in 0.01 N HCl containing 20 mg of polox-
amer-188 and 187 µg of siRNA to make a 10 ml total solution 
in a 50 ml beaker. The final concentration of human IgG in 
each solution amounted to 5 mg/ml. This solution was then 
slowly titrated with 0.01 N NaOH to bring the pH of the mix-
ture to 7, which is the isoelectric point (pI) of human IgG as 
determined in our laboratory using isoelectric focusing. The 
nanoparticles were continuously mixed on a magnetic stirrer 
for additional 10 minutes. At the pI, siRNA-loaded nanopar-
ticles were spontaneously precipitated. The colloidal suspen-
sion was then centrifuged with a micro centrifuge (Eppendorf 
centrifuge 5418) at 2,000 rpm for 5 minutes. The nanoparticles 
were rinsed with double distilled deionized water before being 
redispersed in water and snap-frozen using liquid nitrogen. 
This was then loaded into a freeze-dryer (Labconco Freez-
eZone 4.6), and lyophilization was performed for 48 hours.
Thiolation of anti-NTSR1-mAb. Thiolation of anti-NTSR1-
mAb was performed based on a method adopted from a 
previously used method.18 Briefly, 1.3 × 10−4 mol/l of Traut’s 
reagent (2-Iminothiolane HCl) was prepared in phosphate-
buffered saline (pH 7.4). Further, 500 µl of this solution was 
then added to 1 ml of 1.3 × 10−6 mol/l (0.2 mg/ml) of anti-
NTSR1-mAb solution. The reaction was stirred for 2 hours at 
25 °C. The mixture then centrifuged at 4,000 rpm and 10 °C 
for 15 minutes using 30 kDa cutoff centrifugal ultrafilters (Mil-
lipore Corp.) to exclude unreacted Traut’s reagent.
Activation of hybrid nanoparticles with heterobifunctional 
cross-linker. About 5 mg/ml of hybrid nanoparticles were 
dispersed in 0.1 mol/l phosphate buffer (pH 7.2). This was 
then added to 2 mg/ml of N-[p-maleimidophenyl] isocya-
nate, a heterobifunctional cross-linker that links sulfhydryl 
to hydroxyl groups.10 N-[p-maleimidophenyl] isocyanate was 
dissolved in 50 mmol/l phosphate buffer (pH 8).The reaction 
was performed for 3 hours at 25 °C, after which the activated 
nanoparticles were centrifuged at 4,000 rpm at 10 °C for 15 
minutes using 30 kDa ultrafilters (Millipore Corp.).
Preparation of anti-NTSR1-mAb-functionalized hybrid nano-
particles. The activated nanoparticles were finally function-
alized with the thiolated anti-NTSR1-mAb by adding 500 µl 
of 2 mg/ml thiolated anti-NTSR1-mAb to 4 ml of activated 
nanoparticle suspension (5 mg/ml) and then incubated for 
3 hours at 25 °C. The functionalized nanoparticles were then 
centrifuged for 30 minutes at 4,000 rpm and 10 °C. Uncon-
jugated anti-NTSR1-mAb in the supernatant was quantified 
using Total Protein Kit (Micro Lowry, Sigma) based on the 
supplier’s instructions.
Nanoparticle characterization. Photon correlation spectros-
copy using ZetaSizer Nano ZS (Malvern Instruments, UK) 
was used to measure the particle size and zeta potential of 
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the nanoparticles. Pellets were redispersed in deionized water 
and sonicated for ~5 minutes. Intensity autocorrelation was 
measured at a scattering angle (θ) of 173°. The Z-average 
and polydispersity index were recorded in triplicate. For zeta 
potential, samples were taken in a universal dip cell (Malvern 
Instruments) and the zeta potential recorded in triplicate.
The morphology of nanoparticles was obtained using 
scanning electron microscopy. Powder was layered on a 
scanning electron microscopy stub and spread gently using 
a spatula. Samples were then coated with a thin layer of pal-
ladium. Coated samples were imaged using a Zeiss Supra 
50 V system (Zeiss, Jena, Germany).
Murine models of metastatic NSCLC. Metastatic models of 
NSCLC were created by injecting 5 × 105 A549-luciferase 
cells suspended in sterile phosphate-buffered saline into the 
tail veins of SCID beige mice. Tumor burden was monitored 
using Xenogen IVIS bioluminescence imaging system. About 
100 µl of 30 mg/ml Xenolight Rediject D-Luciferin was admin-
istered by i.p. injection into the mice ~10 minutes before ani-
mals were imaged.
Animal treatment and blood sampling. Tumor-bearing mice 
were divided into two groups. The first group was treated 
with a single dose of 0.9 mg/ml siRNA loaded into anti-
NTSR1-mAb-functionalized hybrid nanoparticles while the 
second group was treated with 0.9 mg/ml naked siRNA. Both 
nanoparticles and naked siRNA were dispersed in sterile 
phosphate-buffered saline. Blood samples were collected 
from three mice per group per time point at 0, 30, and 60 min-
utes and 24, 25, 26, and 48 hours post-dose by retro-orbital 
puncture into ethylenediaminetetraacetic acid tubes. Animals 
were also sacrificed on days 1, 2, and 3 to harvest the lungs, 
kidneys, heart, and livers for analysis. Blood samples were 
mixed with equal amount of lysis-loading buffer of Clarity 
OTX kit (Phenomenex, CA) and stored at −80 °C until ready 
to be used. Tissues were snap-frozen in the liquid nitrogen 
stored at −80 °C before analysis.
siRNA isolation and ion-pair HPLC. siRNA in blood and tissue 
was isolated for HPLC using Clarity OTX kit (Phenomenex) 
with Thermo Scientific HyperSep Vacuum Manifold (Thermo 
Sci National Scientific, Rockwood, TN) according to manu-
facturer’s instructions. Briefly, equal aliquots of Clarity OTX 
loading buffer was mixed with plasma samples prior to load-
ing on the solid-phase extraction cartridge. Solid-phase 
extraction isolation cartridge (Clarity OTX 100 mg/3 ml: Phe-
nomenex) was first wetted with methanol before equilibrating 
with Clarity equilibration buffer (10 mmol/l phosphate, pH 5.5) 
before sample loading. For tissue samples, they were first 
homogenized in 0.1 mol/l Tris buffer, pH 8.0 and then mixed 
with equal amount of lysis-loading buffer. After sample load-
ing, equilibration buffer was added to the cartridge to rinse 
twice before rinses with Clarity OTX wash buffer (10 mmol/l 
phosphate, pH 5.5/50% acetonitrile). Elution buffer (100 
mmol/l ammonium bicarbonate, pH 8.0/40% acetonitrile/10% 
tetrahydrofuran) was then added to elute the siRNA from the 
cartridge. Samples were then speed vacuum evaporated to 
100 µl before liquid chromatography analysis.
Figure 6 shows the schematic of the siRNA isolation pro-
tocol. SiRNA was analyzed using a well-validated ion-pair 
HPLC method.4,19,20 Briefly, analysis was performed using an 
Alliance HPLC system, Waters 2695 Separation Module com-
bined with a Water 2998 photodiode array detector (Waters, 
Milford, MA). A Clarity 3 µm Oligo-RP column (Phenomenex) 
with column dimension 50 × 2.0 mm was used. One microliter 
of siRNA sample was injected using 20 mmol/l triethylamine-
acetic acid (pH 7) and 5–12% acetonitrile, gradient elusion 
as mobile phase. Analysis was performed at a flow rate of 
0.2 ml/minute. UV detection was performed at 269 nm and 
chromatogram was recorded using Empower Prosoftware.
Pharmacokinetic data analysis. Pharmacokinetic parameters 
were estimated using noncompartment analysis of the com-
posite data with WinNonlin software version 6.0 (Pharsight, 
Mountain View, CA).
Statistical analysis. Results are expressed as mean ± SD, 
unless otherwise indicated. Statistically significant difference 
between two groups was determined by two-tailed Student’s 
t-test. A P value of 0.005 was taken as statistically significant.
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